Dublin, Ireland and North Dakota, USA, October 5th 2021
DS Biopharma Limited, a developer of bioactive lipid-based pharmaceuticals and the NDSU Research Foundation today announced they have entered into a license agreement to develop and commercialise novel cancer immunotherapies including Daleuton and delta 5 desaturase (D5D) inhibitors targeting the tumor microenvironment. Daleuton is the synthetically manufactured active pharmaceutical substance Dihomo gamma linolenic acid (DGLA).
Under the terms of the agreement DS Biopharma has exclusively licenced the rights to develop and commercialise small molecule delta 5 desaturase (D5D) inhibitor compounds discovered by North Dakota State University research scientists. The combination of DGLA with the NDSU D5D inhibitors has shown significant reductions in tumor size for multiple cancer types in different animal models.
“This partnership opens up the possibility of a novel platform for oncology treatment. The combination of DGLA and D5D inhibitor directly targets the tumor microenvironment in a synergistic manner providing a new approach to treat multiple solid tumors” said Dr. David Coughlan, Chief Technical Officer of DS Biopharma.
“The agreement provides DS Biopharma with complementary oncology assets and positions Daleuton as part of a targeted cancer therapy. We look forward to working with the NDSU team to further develop this potentially potent treatment” added Mark O’Neill, Chief Executive Officer of DS Biopharma.
“I am delighted to be partnering with DS Biopharma to further develop the great work of the NDSU team in the search for much needed new cancer therapies,” said Dr. Jolynne Tschetter, Executive Director of the NDSU Research Foundation.
Daleuton is the synthetically manufactured active pharmaceutical substance Dihomo gamma linolenic acid (DGLA) and a new chemical entity.
About DS Biopharma
DS Biopharma, headquartered in Dublin, Ireland, is a clinical stage, pharmaceutical company which develops new medicines for unmet needs based on its novel bioactive lipid platform. These lipid molecules have been shown to be crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD). The Company’s lead compound DS107 (Daleuton) is being explored clinically as a topical cream for mild to moderate AD (Phase 3 ready).
About NDSU Research Foundation
NDSU Research Foundation is a 501(c)(3) non-profit corporation that handles the patenting and licensing of technologies that are discovered and developed in NDSU research laboratories. NDSU is a student-focused, land grant, research institution.